Randomised feasibility study evaluating eye movement desensitisation and reprocessing therapy for functional neurological disorder (MODIFI).

Publication date: Jul 08, 2025

Functional neurological disorder (FND) is a common neurological presentation with symptoms such as seizures, walking difficulties, limb weakness and cognitive difficulties. Treatments for FND include physiotherapy and psychological therapy. Eye movement desensitisation and reprocessing therapy (EMDR) is a therapy designed to reduce disturbance associated with distressing or traumatic memories. Case report evidence suggests possible benefit for people with FND. This randomised feasibility study aimed to assess whether a large-scale trial evaluating EMDR for FND would be feasible and acceptable. Fifty participants with FND were randomised to either FND-focused EMDR plus standard neuropsychiatric care (NPC) or NPC alone. Feasibility criteria were recruitment rate, intervention adherence, and outcome measure completion. Assessment of safety was also examined, as well as therapy satisfaction. Participants completed questionnaires at baseline, 3 months, 6 months and 9 months. FND symptoms were assessed using Ecological Momentary Assessment at each time point. Recruitment rate was 58%, intervention adherence was 88%, and outcome measure completion was 68% for Ecological Momentary Assessment and 76% for questionnaires at 9-month follow-up. Participants experienced functional motor symptoms (80%), functional seizures (64%), and cognitive symptoms (32%). Participants receiving EMDR + NPC reported greater satisfaction and greater FND improvement compared to NPC. Questionnaire data suggested greater reductions in PTSD, depression, anxiety, dissociation, disability and healthcare-use for EMDR + NPC. The study demonstrated that an FND-specific protocol for EMDR was feasible and acceptable. Potential positive effects on FND symptoms, mental health, disability, and healthcare utilisation were found. A full-scale trial is warranted to establish efficacy. NCT05455450 ( www. gov ).

Open Access PDF

Concepts Keywords
Desensitisation Adult
Feasibility Aged
Healthcare Feasibility Studies
Nct05455450 Female
Neuropsychiatric Follow-Up Studies
Functional motor disorder
Functional neurological disorder
Functional seizures
Humans
Male
Middle Aged
Nervous System Diseases
Psychological therapy
Randomised controlled trial
Treatment Outcome
Young Adult

Semantics

Type Source Name
disease MESH functional neurological disorder
disease MESH seizures
disease MESH PTSD
disease MESH depression
disease MESH anxiety
disease MESH dissociation
disease MESH neurological disorder
disease MESH tremor
disease MESH brain fog
disease MESH numbness
disease MESH chronic pain
disease MESH irritable bowel syndrome
disease MESH anxiety disorders
disease MESH autistic spectrum disorder
disease MESH alexithymia
drug DRUGBANK Coenzyme M
disease MESH emergency
drug DRUGBANK Trestolone
disease MESH unemployment
disease MESH violence
disease MESH sexual assault
disease MESH bullying
disease MESH Adverse childhood experiences
drug DRUGBANK Isoxaflutole
disease MESH dissociative identity disorder
drug DRUGBANK Aspartame
disease MESH involuntary movements
drug DRUGBANK Methionine
disease MESH migraine
disease MESH syndrome
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Personality disorder
disease MESH Epilepsy
disease MESH suicidal ideation
disease MESH relapse
disease MESH COVID 19
pathway REACTOME Influenza Infection
disease MESH fibromyalgia
disease MESH Crohn’s disease
disease MESH infection
drug DRUGBANK L-Valine
drug DRUGBANK Ethanol
disease MESH eating disorder
drug DRUGBANK Nonoxynol-9
disease MESH death
disease MESH emotional abuse
disease MESH stalking
drug DRUGBANK Ademetionine
disease MESH morbidities
disease MESH tics
drug DRUGBANK Etoperidone
disease MESH Movement Disorders
pathway REACTOME Reproduction
disease MESH motor disorders
disease MESH dissociative seizures
disease MESH tinnitus
drug DRUGBANK Ranitidine
disease MESH mental disorders
disease MESH Psychological Distress

Original Article

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *